BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/28/2026 1:23:41 PM | Browse: 4 | Download: 4
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 120399
DOI 10.4240/wjgs.120399
Country China
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Postoperative circulating tumor DNA detection predicts recurrence and guides adjuvant chemotherapy duration in high-risk stage III colorectal cancer
Manuscript Source Unsolicited Manuscript
All Author List Xiao-Xi Guo, Jian-Zhong Deng, Long-Qing Cheng, Yi-Ban Lin, Ting Cao, Jie-Lan Feng, Ya-Nan Gao, Xian-Sheng Yang and Shan-Shan Liang
Funding Agency and Grant Number
Funding Agency Grant Number
Foshan Self-funded Science and Technology Project No. 2220001004876
Corresponding Author Shan-Shan Liang, Department of Gastrointestinal Surgery, The First People’s Hospital of Foshan (Southern University of Science and Technology Affiliated Foshan Hospital), No. 81 Lingnan Avenue, Chancheng District, Foshan 528248, Guangdong Province, China. lsshan5639@163.com
Key Words Colorectal cancer; Circulating tumor DNA; Recurrence; Adjuvant chemotherapy; Prognosis
Core Tip Postoperative circulating tumor DNA (ctDNA) provides early risk stratification in high-risk stage III colorectal cancer. In this retrospective cohort of 50 patients with T4 or N2 disease, ctDNA positivity four weeks after surgery was independently associated with poorer recurrence-free survival and earlier recurrence, with an approximately fourfold higher adjusted recurrence risk. Exploratory analyses suggested that ctDNA status may help inform adjuvant capecitabine plus oxaliplatin duration, although no significant within-group difference was observed between 3- and 6-month treatment. These findings support ctDNA as a promising biomarker requiring prospective validation.
Citation Guo XX, Deng JZ, Cheng LQ, Lin YB, Cao T, Feng JL, Gao YN, Yang XS, Liang SS. Postoperative circulating tumor DNA detection predicts recurrence and guides adjuvant chemotherapy duration in high-risk stage III colorectal cancer. World J Gastrointest Surg 2026; In press
PDF 120399-in-press.pdf
Received
2026-04-08 10:02
Peer-Review Started
2026-04-08 10:02
First Decision by Editorial Office Director
2026-04-23 03:17
Return for Revision
2026-04-23 03:17
Revised
2026-05-22 15:25
Publication Fee Transferred
2026-05-30 03:35
Second Decision by Editor
2026-07-27 02:44
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-07-28 13:23
Articles in Press
2026-07-28 13:23
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-9366 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com